Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2024 Mar 13

PMID 38477966

Authors

Bryan D Choi

Elizabeth R Gerstner

Matthew J Frigault

Mark B Leick

Christopher W Mount

Leonora Balaj

Sarah Nikiforow

Bob S Carter

William T Curry

Kathleen Gallagher

Marcela V Maus

Affiliations

Soon will be listed here.

Abstract

In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.).

Citing Articles

Clinical Impact of a Next-Generation Sequencing Approach for Glioblastoma Patients.

Vivancos Sanchez C, Esteban Rodriguez M, Pelaez Garcia A, Taravilla-Loma M, Rodriguez-Dominguez V, Rodriguez-Antolin C Cancers (Basel). 2025; 17(5).

PMID: 40075591 PMC: 11898826. DOI: 10.3390/cancers17050744.

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.

Cottrell T, Lotze M, Ali A, Bifulco C, Capitini C, Chow L J Immunother Cancer. 2025; 13(3).

PMID: 40054999 PMC: 11891540. DOI: 10.1136/jitc-2024-010928.

Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer.

Harkos C, Hadjigeorgiou A, Voutouri C, Kumar A, Stylianopoulos T, Jain R Nat Rev Cancer. 2025; .

PMID: 39972158 DOI: 10.1038/s41568-025-00796-w.

Immune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy.

Eckert T, Zobaer M, Boulos J, Alexander-Bryant A, Baker T, Rivers C Cancers (Basel). 2025; 17(3).

PMID: 39941829 PMC: 11816167. DOI: 10.3390/cancers17030462.

Advances in the Repurposing and Blood-Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors.

Rechberger J, Toll S, Biswas S, You H, Chow W, Kendall N Cancers (Basel). 2025; 17(3).

PMID: 39941807 PMC: 11816256. DOI: 10.3390/cancers17030439.

References

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D . HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017; 3(8):1094-1101. PMC: 5747970. DOI: 10.1001/jamaoncol.2017.0184. View

Brown C, Alizadeh D, Starr R, Weng L, Wagner J, Naranjo A . Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016; 375(26):2561-9. PMC: 5390684. DOI: 10.1056/NEJMoa1610497. View

Choi B, Yu X, Castano A, Bouffard A, Schmidts A, Larson R . CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019; 37(9):1049-1058. DOI: 10.1038/s41587-019-0192-1. View

Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris M, Serra A . GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023; 388(14):1284-1295. DOI: 10.1056/NEJMoa2210859. View

Vitanza N, Wilson A, Huang W, Seidel K, Brown C, Gustafson J . Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Cancer Discov. 2022; 13(1):114-131. PMC: 9827115. DOI: 10.1158/2159-8290.CD-22-0750. View

Hobbs J, Nikiforova M, Fardo D, Bortoluzzi S, Cieply K, Hamilton R . Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Am J Surg Pathol. 2012; 36(8):1186-93. PMC: 3393818. DOI: 10.1097/PAS.0b013e3182518e12. View

van den Bent M, Gao Y, Kerkhof M, Kros J, Gorlia T, van Zwieten K . Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol. 2015; 17(7):935-41. PMC: 5762005. DOI: 10.1093/neuonc/nov013. View

Batool S, Muralidharan K, Hsia T, Falotico S, Gamblin A, Rosenfeld Y . Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients. Clin Cancer Res. 2022; 28(18):4070-4082. PMC: 9475243. DOI: 10.1158/1078-0432.CCR-22-0444. View

ORourke D, Nasrallah M, Desai A, Melenhorst J, Mansfield K, Morrissette J . A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017; 9(399). PMC: 5762203. DOI: 10.1126/scitranslmed.aaa0984. View

10.

Amini L, Silbert S, Maude S, Nastoupil L, Ramos C, Brentjens R . Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022; 19(5):342-355. DOI: 10.1038/s41571-022-00607-3. View

11.

Choi B, Gedeon P, Herndon 2nd J, Archer G, Reap E, Sanchez-Perez L . Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunol Res. 2014; 1(3):163. PMC: 3932050. DOI: 10.1158/2326-6066.CIR-13-0049. View

12.

Choi B, Kuan C, Cai M, Archer G, Mitchell D, Gedeon P . Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A. 2012; 110(1):270-5. PMC: 3538214. DOI: 10.1073/pnas.1219817110. View

13.

Majzner R, Ramakrishna S, Yeom K, Patel S, Chinnasamy H, Schultz L . GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022; 603(7903):934-941. PMC: 8967714. DOI: 10.1038/s41586-022-04489-4. View